Year-End Review of Upcoming Treatments for ALS

While some progress has been made in the treatment of ALS, combination therapies with drugs that target other pathways, alongside stem cell technology, are sorely needed

Biogen Idec Sees Game Changer in ALS Drug

Patients given higher doses got better results. “It was a nice dose-dependent effect,’’ he said. “We didn’t expect that at 12 weeks.’’

Dexpramipexole appears to slow symptom progression and reduce mortality in Phase 2 trial

Results of the first stage showed that receiving dexpramipexole appeared to slow the progression of symptoms measured both by the ALS Functional Rating Scale and by pulmonary capacity. The second stage had similar results, with slower disease progression and a reduced risk of death in participants receiving the higher dosage.